$2.11
-0.09[-4.09%]
At close: Apr 23
$2.11
0[0.00%]
After Hours: 5:04AM EDT
Regulus Therapeutics
(NASDAQ:RGLS)Latest News for Regulus Therapeutics Stock (NASDAQ:RGLS)
Regulus Therapeutics Stock (NASDAQ: RGLS)
Categories: All
Monday, March 25, 2024
Thursday, March 21, 2024
Tuesday, March 19, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
Wednesday, March 13, 2024
- Regulus Therapeutics shares are trading higher after Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $2 to $3.Benzinga Newsdesk - Mar 13, 2024, 1:58PM
- Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3Benzinga Newsdesk - Mar 13, 2024, 6:53AM
Tuesday, March 12, 2024
- Gold Down Over 1%; ClearOne Shares Spike HigherAvi Kapoor - Mar 12, 2024, 2:57PM
- Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 12, 2024, 2:07PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Mar 12, 2024, 1:31PM
- Nasdaq Surges Over 1%; Blade Air Mobility Shares PlummetAvi Kapoor - Mar 12, 2024, 12:10PM
- Regulus Therapeutics Shares Resume TradeBenzinga Newsdesk - Mar 12, 2024, 11:22AM
- Regulus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 116.7%Benzinga Newsdesk - Mar 12, 2024, 11:17AM
- Dow Gains 100 Points; US Inflation Rate Rises To 3.2% In FebruaryAvi Kapoor - Mar 12, 2024, 10:11AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 12, 2024, 9:05AM
- Market-Moving News for March 12thBenzinga Newsdesk - Mar 12, 2024, 8:43AM
- Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?Vandana Singh - Mar 12, 2024, 8:08AM
- Regulus Therapeutics shares are trading higher after the company announced topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company announced an oversubscribed $100 million private placement of equity.Benzinga Newsdesk - Mar 12, 2024, 7:55AM
- Regulus Therapeutics Announces Oversubscribed $100M Private Placement Of Equity; Investors Will Purchase The Shares At $1.60/ShareBenzinga Newsdesk - Mar 12, 2024, 6:34AM
- Regulus Therapeutics Released Topline Data From The Second Cohort Of Patients In Its Phase 1b Multiple-Ascending Dose Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney DiseaseBenzinga Newsdesk - Mar 12, 2024, 6:32AM
Tuesday, January 02, 2024
Thursday, November 02, 2023
Thursday, September 21, 2023
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Sep 21, 2023, 5:31PM
- Analyst Expectations for Regulus Therapeutics's FutureBenzinga Insights - Sep 21, 2023, 1:00PM
- Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $12Benzinga Newsdesk - Sep 21, 2023, 11:25AM
- HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price TargetBenzinga Newsdesk - Sep 21, 2023, 6:29AM
Wednesday, September 20, 2023
- Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney DiseaseVandana Singh - Sep 20, 2023, 12:53PM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Sep 20, 2023, 9:06AM
- Regulus Therapeutics Announced Topline Results From The First Cohort Of Its Phase 1B MAD Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease, Demonstrating Statistically Significant Increase In Urinary Polycystin 1Benzinga Newsdesk - Sep 20, 2023, 7:02AM
Tuesday, September 19, 2023
Wednesday, September 13, 2023
Tuesday, August 15, 2023
- President and CEO at Regulus Therapeutics Acquires Company Stock Options Worth 1,312,500 SharesBenzinga Insights - Aug 15, 2023, 11:03AM
- Regulus Therapeutics Chief Financial Officer Awarded $487K Worth of Stock OptionsBenzinga Insights - Aug 15, 2023, 11:03AM
- Regulus Therapeutics Director Awarded $19K Worth of Stock OptionsBenzinga Insights - Aug 15, 2023, 11:03AM
- Regulus Therapeutics Board Member Awarded $19K Worth of Stock OptionsBenzinga Insights - Aug 15, 2023, 11:02AM
- Director at Regulus Therapeutics Acquires Company Stock Options Worth 15,000 SharesBenzinga Insights - Aug 15, 2023, 11:02AM
Thursday, August 10, 2023
Tuesday, August 08, 2023
Wednesday, June 28, 2023
Wednesday, June 21, 2023
Wednesday, June 14, 2023
- Regulus Therapeutics Director Awarded $43K Worth of Stock OptionsBenzinga Insights - Jun 14, 2023, 11:02AM
- Regulus Therapeutics Board Member Awarded $43K Worth of Stock OptionsBenzinga Insights - Jun 14, 2023, 11:02AM
- Director at Regulus Therapeutics Acquires Company Stock Options Worth 30,000 SharesBenzinga Insights - Jun 14, 2023, 11:02AM